Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elpipodect (MK-8189) MAD Study in Schizophrenia
NCT05406440Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of elpipodect in schizophrenia (4 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Experiencing an Adverse Event at 17 days and Number of Participants Who Discontinue From Study Treatment Due to an AE at 3 days. Started Jul 2022; status: completed.
02
Drugs
elpipodect
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05406440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05406440.